Gilles Montalescot1, Jean-Philippe Collet2, Patrick Ecollan3, Leonardo Bolognese4, Jurrien Ten Berg5, Dariusz Dudek6, Christian Hamm7, Petr Widimsky8, Jean-François Tanguay9, Patrick Goldstein10, Eileen Brown11, Debra L Miller11, LeRoy LeNarz11, Eric Vicaut12. 1. ACTION Study Group, Institut de Cardiologie, UPMC Université Paris 6, INSERM UMRS-1166 Paris, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr. 2. ACTION Study Group, Institut de Cardiologie, UPMC Université Paris 6, INSERM UMRS-1166 Paris, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France. 3. ACTION Study Group, SMUR, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France. 4. Cardiovascular and Neurological Department, Azienda Ospedaliera, Arezzo, Italy. 5. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. 6. Institute of Cardiology, Jagiellonian University Medical College, University Hospital, Krakow, Poland. 7. Kerckhoff Heart and Thoraxcenter, Bad Nauheim and Medical Clinic I, University of Giessen, Giessen, Germany. 8. Third Medical Faculty of Charles University and University Hospital Royal Vineyards, Prague, Czech Republic. 9. Montreal Heart Institute, Montreal, Quebec, Canada. 10. SAMU and Emergency Department, Lille University Hospital, Lille, France. 11. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana. 12. ACTION Study Group, Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisière (AP-HP), Université Paris 7, Paris, France.
Abstract
BACKGROUND: After percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is recommended for 1 year. OBJECTIVES: The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but it is unknown if administration before the start of PCI is beneficial. METHODS: In the randomized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treatment withprasugrel (30-mg loading dose), and 1,376 received placebo. At the time of PCI, patients who received pre-treatment with prasugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a 60-mg loading dose of prasugrel. Primary efficacy was a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa bailout through 7 days from randomization. Investigators captured the presence of thrombus on initial angiography and during PCI. RESULTS: The incidence of the primary endpoint through 7 days from randomization in the pre-treatment group versus the no pre-treatment group was 13.1% versus 13.1% (p = 0.93). Pre-treatment with prasugrel was not associated with decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3-fold higher incidence of the primary endpoint than patients without thrombus. There was no impact of pre-treatment with prasugrel on the presence of thrombus before PCI or on occurrence of stent thrombosis after PCI. There was a 3-fold increase in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleeding and a 6-fold increase in non-coronary artery bypass graft life-threatening bleeding with pre-treatment with prasugrel; the same trends persisted in patients who had radial or femoral access even with use of a closure device. CONCLUSIONS: These findings support deferring treatment with prasugrel until a decision is made about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission. (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction [ACCOAST]; NCT01015287).
RCT Entities:
BACKGROUND: After percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is recommended for 1 year. OBJECTIVES: The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but it is unknown if administration before the start of PCI is beneficial. METHODS: In the randomized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received placebo. At the time of PCI, patients who received pre-treatment with prasugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a 60-mg loading dose of prasugrel. Primary efficacy was a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa bailout through 7 days from randomization. Investigators captured the presence of thrombus on initial angiography and during PCI. RESULTS: The incidence of the primary endpoint through 7 days from randomization in the pre-treatment group versus the no pre-treatment group was 13.1% versus 13.1% (p = 0.93). Pre-treatment with prasugrel was not associated with decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3-fold higher incidence of the primary endpoint than patients without thrombus. There was no impact of pre-treatment with prasugrel on the presence of thrombus before PCI or on occurrence of stent thrombosis after PCI. There was a 3-fold increase in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleeding and a 6-fold increase in non-coronary artery bypass graft life-threatening bleeding with pre-treatment with prasugrel; the same trends persisted in patients who had radial or femoral access even with use of a closure device. CONCLUSIONS: These findings support deferring treatment with prasugrel until a decision is made about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission. (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction [ACCOAST]; NCT01015287).
Authors: Charles V Pollack; Farideh Davoudi; Deborah B Diercks; Richard C Becker; Stefan K James; Soo Teik Lim; Phillip J Schulte; Jindrich Spinar; Philippe Gabriel Steg; Robert F Storey; Anders Himmelmann; Lars Wallentin; Christopher P Cannon Journal: Clin Cardiol Date: 2017-06-09 Impact factor: 2.882
Authors: Maximilian Tscharre; Florian Egger; Matthias Machata; Miklos Rohla; Nadia Michael; Manuel Neumayr; Robert Zweiker; Johannes Hajos; Christopher Adlbrecht; Markus Suppan; Wolfgang Helmreich; Bernd Eber; Kurt Huber; Thomas W Weiss Journal: PLoS One Date: 2017-06-20 Impact factor: 3.240
Authors: Pedro Gabriel Melo de Barros e Silva; Henrique Barbosa Ribeiro; Antônio Claudio do Amaral Baruzzi; Expedito Eustáquio Ribeiro da Silva Journal: Arq Bras Cardiol Date: 2016-03 Impact factor: 2.000
Authors: T Yetgin; E Boersma; P C Smits; A G de Vries; E Huijskens; F Zijlstra; M M J M van der Linden; R J M van Geuns Journal: Neth Heart J Date: 2018-08 Impact factor: 2.380